(ANSA) – ROME, FEB 21 – The experimental molecule zuranolone appears to be effective and rapid in reducing depressive symptoms in so-called major depression, especially if administered in combination with a standard antidepressant drug. This was highlighted by Sage Therapeutics and Biogen, who announce that the Phase 3 Coral study has achieved its objectives. He did this by demonstrating a rapid and statistically significant reduction in depressive symptoms on day 3 and over the course of two weeks of treatment.
This evidence was demonstrated at the first follow-up, which occurred on day 3 from the start of administration of 50 mg zuranolone in combination with a tricyclic antidepressant drug (ADT), and ascertained by detecting a change in the Hamilton depression rating scale. Administration of zuranolone in the amount of 50 mg concomitantly with a standard antidepressant drug in the study in 210 patients compared with 215 others was generally well tolerated. Most adverse events reported during treatment were mild or moderate and no specific adverse events were identified requiring further investigation.
“The results of the Coral study – said Sagar Parikh, an expert in depression and professor of Clinical Neuroscience and Psychiatric Sciences at the University of Michigan – were particularly interesting because they showed that, in the course of a few days, zuranolone produced a rapid reduction in depressive symptoms compared to current ADTs, which in clinical practice can take weeks or months to function. ” (HANDLE).
breaking latest news © Copyright ANSA
